Health·August 11, 2026·2 min readWebsite Exclusive

Bristol Myers Squibb Picks Houston for $2.3B Manufacturing Campus

500 permanent jobs planned at 600,000-square-foot Generation Park site

Oil refinery complex with distillation towers and industrial piping.
File photoOil refinery complex with distillation towers and industrial piping.CC0 Public Domain

Bristol Myers Squibb announced on August 10, 2026, that it will invest $2.3 billion to build a major pharmaceutical manufacturing campus at Generation Park in northeast Houston, Texas. The approximately 600,000-square-foot facility is expected to create nearly 500 skilled permanent jobs and about 2,000 construction-related jobs as the project is built between 2027 and 2030.

The company said the new site will use flexible manufacturing systems capable of producing several types of medicines, including small-molecule drugs, biologics and antibody-drug conjugates. That design gives Bristol Myers Squibb the ability to shift production as its drug pipeline and manufacturing needs change rather than dedicating the entire facility to a single type of medicine.

The Houston project is part of Bristol Myers Squibb's broader commitment to invest $40 billion in the United States over five years across research and development, technology and manufacturing. CEO Christopher Boerner said the company sees continued U.S. leadership in biopharmaceutical innovation as important to its long-term strategy. Other major pharmaceutical companies have also announced multibillion-dollar expansions of U.S. manufacturing capacity in recent years.

Texas is providing financial incentives for the project. Gov. Greg Abbott said Bristol Myers Squibb will receive a $4.89 million Texas Enterprise Fund grant, and the project also qualifies for additional state benefits. Houston-area economic development officials have promoted the region's medical institutions, workforce and available industrial sites as they work to expand the area's life-sciences manufacturing sector.

The project also adds to growing pharmaceutical investment around Houston. Eli Lilly previously announced plans for another multibillion-dollar manufacturing facility in the region, giving local officials two major pharmaceutical manufacturing projects as they seek to establish Houston as a larger life-sciences production center.

Bristol Myers Squibb expects the Generation Park facility to be completed around 2030, with the company saying the site could expand further as manufacturing demand grows.

Community discussion
"With nearly 500 permanent positions expected, how much could investments like this change Houston's role in U.S. pharmaceutical manufacturing?"